Altimmune to Present at Upcoming Investor Conferences
05/16/2022 - 07:30 AM
GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in May 2022:
H.C. Wainwright Global Investment Conference Tuesday, May 24, 20227:00 am Eastern Time The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.B. Riley Securities Institutional Investor Conference Thursday, May 26, 20221:00 pm Pacific Time The session will be an in person fireside chat.About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com .
Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on Twitter
Altimmune Investor & Media Contact:
Richard Eisenstadtreisenstadt@altimmune.com
ALT Rankings
#5342 Ranked by Stock Gains
ALT Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Commercial Services, Miscellaneous Commercial Services, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Gaithersburg
About ALT
altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current
